Amicus Therapeutics, Inc.
It’s not simple tracking down the five most expensive perquisites. They’re in the Summary Compensation Table (SCT) in a company’s proxy statement but are buried in a category called “All Other Compensation” (AOC). AOC is, as its name suggests, a catch-all for anything that won’t fit into any of the other pay categories defined by the Securities and Exchange Commission (SEC). For that reason there are more »
Buckeye Partners (NYSE: BPL) recently announced plans to issue additional limited partnership units. Citigroup (NYSE: C) issued preferred shares to the government in 2008 during the financial meltdown. Simon Properties Group (NYSE: SPG) issued shares in early 2012 and again in late 2012. How can you tell if these corporate actions are good or bad for shareholders?
A number of biotechs of all sizes saw significant price action last week, specifically on Friday. It wasn’t just gainers that made the headlines, but also stocks seeing a significant decline. Therefore, I am looking at the best and worst, performing biotechs to determine what moved them and how to play the movement.
Dendreon (NASDAQ: DNDN)
Dendreon is probably the most controversial biotech stock in the market, due to more »
Biotechnolgy is the ultimate industry of speculation. As investors, we learn to invest on fundamentals, but when investing in this particular space, the stocks are moved by rumors and news that “might” indicate a future FDA approval. With that being said, let’s look at a few of the industry’s biggest movers on Friday; those that might trade higher in 2013.
Cytokinetics, Inc more »
In the first part of this article, I wrote about four companies that could have possible catalysts in November, because a good investment strategy is to anticipate future movements of these companies. Biopharmaceutical companies are typically reevaluated weeks before presenting results of their studies or future meetings with the FDA.
In the second part of this article, I will write about other companies that have possible catalysts in November.
Another more »
I am particularly smitten with health care penny stocks. Investing in so-called penny stocks is certainly attractive. But rampant speculation followed by investment in unregulated market can lead the portfolio to go haywire. Therefore extensive research and understanding the business is of real importance rather than being taken for a ride. Penny stocks have a solid reputation for being a risky investment; however, if the potential rewards excite you, then more »